GLP-1/Glucagon Dual Agonists: Mechanism of Action, Clinical Pipeline, and Research Outlook 2026

Industry Authority | 2026-07-10 | 13 min read

An industry-grade 2026 review of GLP-1/glucagon dual agonists: receptor pharmacology, energy expenditure, hepatic lipid oxidation, clinical pipeline (mazdutide, survodutide, pemvidutide), and research implications.

Introduction: why GLP-1/glucagon dual agonism matters

The GLP-1 receptor agonist class — semaglutide, liraglutide, dulaglutide — transformed metabolic disease research. But GLP-1 mono-agonism has a ceiling: significant but moderate weight loss (12-15% in clinical trials), limited effects on hepatic steatosis, and modest improvements in lipid metabolism.

Adding glucagon receptor (GCGR) agonism breaks this ceiling. The combination produces:

  • Greater weight loss (18-22% in dual agonist Phase 2 trials)
  • Reduced hepatic steatosis via direct hepatic lipid oxidation
  • Increased energy expenditure through thermogenesis
  • Improved lipid profiles independent of weight loss
  • Synergistic glycemic control

This 2026 review covers the molecular pharmacology, clinical pipeline, and research outlook for GLP-1/glucagon dual agonists.

Molecular basis of dual agonism

Receptor pharmacology

GLP-1R and GCGR belong to the class B1 GPCR family (secretin-like). They share structural homology but have distinct binding pockets and signaling pathways.

  • **GLP-1R signaling**: Gαs-mediated cAMP elevation, β-arrestin recruitment, appetite suppression in the hypothalamus, glucose-dependent insulin secretion
  • **GCGR signaling**: Gαs-mediated cAMP elevation, glycogenolysis, gluconeogenesis, hepatic lipid oxidation, thermogenic gene expression

A dual agonist must activate both receptors, ideally with balanced potency to avoid GCGR-driven hyperglycemia (the natural concern with glucagon agonism).

The oxyntomodulin template

Oxyntomodulin (OXM) is a 37-amino acid proglucagon-derived peptide containing the full GLP-1 sequence (7-37) plus an 8-amino acid C-terminal extension. It activates both GLP-1R and GCGR with roughly balanced potency (EC50 values within 2-3 fold).

Most clinical dual agonists are chimeric peptides derived from:

  • GLP-1 (positions 1-29) for GLP-1R affinity
  • Glucagon (positions 12-29, modified) for GCGR affinity
  • Aib (aminoisobutyric acid) at position 2 to prevent DPP-4 degradation
  • C20 fatty diacid conjugation for albumin binding and extended half-life

Engineering balanced potency

Achieving the right GLP-1R:GCGR potency ratio is critical:

  • Too much GLP-1R bias → reduced energy expenditure, less hepatic benefit
  • Too much GCGR bias → hyperglycemia risk, nausea, tachycardia

Lead clinical candidates have optimized this ratio through medicinal chemistry:

  • Survodutide: balanced 1:1 GLP-1R/GCGR potency
  • Mazdutide: GLP-1R-biased (approximately 2:1)
  • Pemvidutide: GLP-1R-biased (approximately 1.5:1)

Clinical pipeline: GLP-1/glucagon dual agonists

Survodutide (BI 456906)

Boehringer Ingelheim's survodutide is one of the most clinically advanced dual agonists:

  • **Mechanism**: Balanced GLP-1R/GCGR agonism, acylated for weekly dosing
  • **Phase 2 results** (NCT04153929): Up to 18.7% body weight reduction at 46 weeks (4.8 mg dose)
  • **Phase 3 program**: Synchronicity trials in obesity and MASH (metabolic dysfunction-associated steatohepatitis)
  • **Differentiation**: Strong hepatic steatosis data — primary endpoint in MASH trials

Mazdutide (IBI362)

Innovent Biologics' mazdutide is China's first dual agonist:

  • **Mechanism**: GLP-1R-biased dual agonism, once-weekly acylated peptide
  • **Phase 2 results**: 12-15% body weight reduction at 24 weeks (9 mg dose)
  • **Phase 3 program**: GLORY-1 (obesity), GLORY-2 (T2DM with obesity), DREAMS-1 (MASH)
  • **Differentiation**: First dual agonist approved for marketing in China (2025)

Pemvidutide (Terns Pharmaceuticals)

Pemvidutide is a peptide designed for MASH and obesity:

  • **Mechanism**: GLP-1R/GCGR dual agonism with lipid-lowering activity
  • **Phase 2 results (MASH)**: Significant reduction in liver fat content at 12 weeks
  • **Differentiation**: Targets MASH as primary indication rather than obesity

Efinopegdutide (HM15136)

Hanmi Pharmaceutical's efinopegdutide uses a different scaffold:

  • **Mechanism**: GLP-1R/GCGR dual agonism with PEGylation for extended half-life
  • **Phase 2 results**: 12-15% body weight reduction, significant liver fat reduction
  • **Differentiation**: Validated in MASH populations

Mechanism of action: how dual agonism produces superior effects

Energy expenditure

GCGR activation in hepatocytes triggers:

  • Increased fatty acid oxidation
  • Increased mitochondrial uncoupling (UCP1, UCP3 upregulation)
  • Increased resting energy expenditure (measured in humans via indirect calorimetry)

Animal studies show dual agonists increase energy expenditure by 8-12% above baseline, an effect not seen with GLP-1 mono-agonists.

Hepatic lipid metabolism

Dual agonism directly targets hepatic steatosis:

  • Reduced de novo lipogenesis
  • Increased β-oxidation of fatty acids
  • Reduced VLDL secretion
  • Improved mitochondrial function

This is the primary rationale for dual agonists in MASH/NASH clinical development.

Appetite suppression

GLP-1R-mediated appetite suppression is preserved in dual agonists:

  • Hypothalamic POMC neuron activation
  • Brainstem area postrema signaling
  • Gastric emptying delay

The combination produces greater appetite suppression than GLP-1 alone, because GCGR activation in the hypothalamus also contributes to satiety.

Glycemic control

Despite the hyperglycemic potential of GCGR agonism, dual agonists show:

  • Reduced fasting glucose
  • Reduced HbA1c (1.5-2.0% reductions)
  • Improved glucose tolerance

The mechanism: GLP-1R-driven insulin secretion offsets GCGR-driven glucose production, and the net effect depends on the GLP-1R:GCGR potency ratio.

Research applications and sourcing

GLP-1/glucagon dual agonist research peptides enable studies in:

  • **Energy expenditure**: indirect calorimetry, metabolic cage studies
  • **Hepatic steatosis**: NAFLD/MASH models, liver histology, lipid assays
  • **Body composition**: DEXA, MRI-based fat quantification
  • **Glycemic control**: oral glucose tolerance tests, hyperinsulinemic-euglycemic clamps
  • **Cardiovascular effects**: blood pressure, lipid panels, vascular function

Sourcing requirements for dual agonist research:

  • HPLC purity ≥95% (preferably ≥98% for quantitative studies)
  • Mass spectrometry identity confirmation
  • Endotoxin testing (<1.0 EU/mg for in vivo studies)
  • Cold-chain shipping for acylated peptides

Outlook: the next generation

Beyond GLP-1/glucagon, the next frontier includes:

  • **GLP-1/GIP/glucagon triple agonists** (retatrutide is the prototype)
  • **GLP-1/GIP/GLP-2 triple agonists** targeting gut barrier function
  • **GLP-1/NPY dual agonists** targeting central appetite pathways
  • **Tissue-targeted GLP-1R agonists** with reduced CNS penetration

These next-generation agents will require custom synthesis, careful purity validation, and rigorous COA review.

Summary

GLP-1/glucagon dual agonism represents a meaningful advance over GLP-1 mono-agonism. The mechanism — combining appetite suppression, energy expenditure, and hepatic lipid oxidation — produces clinical effects beyond what either receptor can achieve alone. With multiple Phase 3 programs in obesity and MASH, dual agonists are poised to become the next standard of care in metabolic disease.

For research laboratories, sourcing high-purity dual agonist peptides with complete analytical documentation is the foundation for reproducible, publication-quality studies.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides